FDA approves treatment for chronic graft versus host disease
August 3, 2017 – The U.S. Food and Drug Administration today expanded the approval of Imbruvica (ibrutinib) for the treatment of adult patients with chronic graft versus host…
Please share your feedback! We’re interested to learn more about your experience with American Nurse Journal.